Pfizer (NYSE:PFE) reported that its BRAFTOVI combination therapy produced significant progression free survival benefits in ...

Pfizer (PFE) stock is in focus as colorectal cancer therapy Braftovi as part of a combination regimen succeeds in a ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology with an established presence in breast, genitourinary, thoracic, gastrointestinal cancer and blood cancers. It boasts a ...

Pfizer (NYSE:PFE) reported positive topline results from its pivotal BREAKWATER trial. The study evaluated a BRAFTOVI based combination in previously untreated metastatic colorectal cancer with a BRAF ...

Men’s Health Network debuts “My Cancer, My Plan” Podcast to help men navigate diagnosis, treatment decisions, and ...

Pfizer Inc. PFE on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer. Pfizer ...

ZERO Prostate Cancer (ZERO) announces the 2026 ZERO Prostate Cancer Advocacy Summit will take place in person at the Hilton Washington, D.C. Capitol Hill, just steps away from the offices of the ...

Pfizer Inc. (NYSE:PFE) is among the Best Affordable Stocks Under $40 to Buy. On February 17, Pfizer Inc. (NYSE:PFE) announced positive results from its key BREAKWATER trial, which is testing BRAFTOVI ...

This recent readout follows successful data from another combination including Braftovi in mCRC.

Pfizer announces positive results from pivotal BREAKWATER trial of Braftovi in combo with cetuximab & Folfiri in patients with metastatic colorectal cancer: New York Wednesday, Fe ...

Chinese pharmaceutical companies that as a group chalked up record outbound licensing agreements with international industry ...